Athersys (NASDAQ:ATHX) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Athersys and Immutep, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Athersys | 0 | 0 | 4 | 0 | 3.00 |
Immutep | 0 | 0 | 2 | 0 | 3.00 |
Athersys presently has a consensus price target of $9.00, indicating a potential upside of 341.18%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Athersys' higher possible upside, equities analysts plainly believe Athersys is more favorable than Immutep.
Profitability
This table compares Athersys and Immutep's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Athersys | N/A | -176.56% | -112.67% |
Immutep | N/A | N/A | N/A |
Volatility & Risk
Athersys has a beta of -1.54, indicating that its stock price is 254% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.
Insider and Institutional Ownership
27.9% of Athersys shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Athersys and Immutep's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Athersys | $5.63 million | 71.64 | $-44,580,000.00 | ($0.29) | -7.03 |
Immutep | $4.92 million | 21.24 | $-9,040,000.00 | N/A | N/A |
Immutep has lower revenue, but higher earnings than Athersys.
Summary
Athersys beats Immutep on 6 of the 10 factors compared between the two stocks.